StocksMedium•8 October 2026•
1 min read
Biohaven Signs $100 Million Licensing Deal with Ono Pharmaceutical for Asian Expansion
Key Facts
1Biohaven signed a $100 million licensing agreement with Japan's Ono Pharmaceutical.
2The agreement covers Biohaven's Phase 3 MoDE pan IgG degrader portfolio.
Biohaven signed a $100 million licensing agreement with Japan's Ono Pharmaceutical. Benzinga reported that the deal is designed to expand Biohaven's footprint in the Asian market by leveraging Ono's regional commercialization expertise.
The agreement covers Biohaven's Phase 3 MoDE pan IgG degrader portfolio. Regarding equity performance, BHVN closed at $11.88 on October 7, 2026, while Ono Pharmaceutical's stock 4528.T closed at 2257.5 JPY on the same date.